Valeant Pharma (VRX) Tops Q4 EPS by 5c; Guides In-Line
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Valeant Pharmaceuticals (VRX) PT Lowered to $18 at Jefferies
March 1, 2017 7:46 AM ESTJefferies lowered its price target on Valeant Pharmaceuticals (NYSE: VRX) to $18.00 (from $22.00) while maintaining a Buy rating following Q4 result and outlook.
Analyst David Steinberg commented, "Q4 EPS of $1.26 was ~5% ahead of cons with revs just topping guidance ($2.28-2.38B) at $2.40B. More importantly,... More
